(a) In accordance with Chapter 1003 of the Texas Health and Safety Code, each IRB overseeing clinical trials of investigational stem cell treatments must submit an annual report to the board that:(1) sets forth the study's current findings;(2) specifies the number of patients participating in the trial(s);(3) documents the treatment results for patients, as applicable;(4) generally describes the effects of the treatments including all adverse events;(5) outlines the study's findings to date;(6) identifies the medical school or hospital the IRB is affiliated with;(7) provides the location where the patients' treatments were provided in accordance with §1003.055 of the Texas Health and Safety Code; and(8) includes the names of all physicians certified by the IRB or the affiliated entity and the time-period of that certification.(b) The annual report shall not include any patient identifying information.(c) The annual report shall cover the time period beginning September 1 and ending on August 31.(d) The report must be submitted to the board before the end of the calendar year in which the reporting time period ends.